Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Income from Continuing Operations (2017 - 2025)

UroGen Pharma (URGN) has disclosed Income from Continuing Operations for 9 consecutive years, with 26364000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 29.72% year-over-year to 26364000.0, compared with a TTM value of 153494000.0 through Dec 2025, down 20.98%, and an annual FY2025 reading of 153494000.0, down 20.98% over the prior year.
  • Income from Continuing Operations was 26364000.0 for Q4 2025 at UroGen Pharma, up from 33347000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 21879000.0 in Q3 2023 and bottomed at 49940000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 30160750.0, with a median of 28422000.0 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations skyrocketed 32.74% in 2021, then tumbled 49.51% in 2025.
  • Year by year, Income from Continuing Operations stood at 28452000.0 in 2021, then dropped by 1.47% to 28869000.0 in 2022, then increased by 9.88% to 26016000.0 in 2023, then tumbled by 44.19% to 37512000.0 in 2024, then grew by 29.72% to 26364000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for URGN at 26364000.0 in Q4 2025, 33347000.0 in Q3 2025, and 49940000.0 in Q2 2025.